Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.
The addition of zoledronic acid to aromatase inhibitors is associated with improved bone mineral density, but not with an effect on clinically-meaningful end points such as fractures. The oncology community should prioritize the design of trials evaluating more relevant end points, such as fragility fracture risk, for treatment-induced bone loss and critically assess the effects of such treatment on breast cancer survival.
Amir
Eitan
E
Division of Medical Oncology, University of Toronto and Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada. eitan.amir@uhn.on.ca
Ocaña
Alberto
A
Seruga
Bostjan
B
Josse
Robert
R
Clemons
Mark
M
D015502:Absorptiometry, Photon; D047072:Aromatase Inhibitors / Q000009:adverse effects; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D016001:Confidence Intervals; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006305:Health Status Indicators; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D015994:Incidence; D016017:Odds Ratio; D012307:Risk Factors; D040242:Risk Reduction Behavior; D000077211:Zoledronic Acid
D047072:Aromatase Inhibitors; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid